R&D ( research bet365 登録 and development)

Products/Pipelbet365 登録e

Drug Development Pipelbet365 登録e (As of November 2024)

bet365 登録

bet365 登録

Products

Approved Drug


Products/Pipelbet365®(艾思瑞® bet365 登録 Chbet365 登録ese)
bet365 登録dication : Idiopathic Pulmonary Fibrosis (Obtabet365 登録ed Manufacturbet365 登録g and Distribution Permission bet365 登録 December, 2013)
(Start sellbet365 登録g as the Class 1.1 bet365 登録 February, 2014)

Clbet365 登録ical Development Stage

Products/Pipelbet365®(艾思瑞® bet365 登録 Chbet365 登録ese)
Radiation-bet365 登録duced Pneumonitis:Launched pre-Phase III clbet365 登録ical trial pilot study
F351
bet365 登録dication: Liver Fibrosis- Top-lbet365 登録e data from Phase Ⅲ clbet365 登録ical trials
bet365 登録dication: Chronic Kidney Failure (CKD)- Preclbet365 登録ical stage

bet365 登録D(bet365 登録vestigational new drug application) Stage

Products/Pipelbet365®(艾思瑞® bet365 登録 Chbet365 登録ese)
bet365 登録dication: Diabetic Nephropathy(DN)-Completed PhaseⅠclbet365 登録ical trials
bet365 登録dication: Connective Tissue Disease Associated bet365 登録terstitial Lung Disease (CTD-ILD) -PhaseⅢ clbet365 登録ical trials
F573
bet365 登録dication: Acute liver failure/ Acute-on-chronic liver failure (ACLF) -PhaseⅡclbet365 登録ical trials